Skip to content

Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB

Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB (The REMOTE Study)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03104179
Acronym
REMOTE
Enrollment
80
Registered
2017-04-07
Start date
2017-05-31
Completion date
2019-05-31
Last updated
2017-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracorporeal Circulation, Hemofiltration

Brief summary

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response. They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery. Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments. These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure. There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay. Use of cytokine adsorption within the extracorporeal circuit during CBP can affect the circulating cytokine levels during and after CPB and lead to a diminished inflammatory response, acute phase reaction as well as reduction of organ failure.

Detailed description

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response. They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery. Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments. These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure. There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay. Use of cytokine adsorption within the extracorporeal circuit during CBP can affect the circulating cytokine levels during and after CPB and lead to a diminished inflammatory response, acute phase reaction as well as reduction of organ failure. Official Title: Removal of Cytokines in patients undergoing cardiac surgery with CPB ( The REMOTE Study) Study type: Interventional Study design: randomized, controlled Endpoint Classification: Efficacy study Interventional Model: Parallel assignment Masking: Single blinding ( Subject) Primary purpose: Treatment Patients who have an elective cardiac surgery with an expected CPB duration \> 75 min ( e.g. valve surgery, CABG, combined procedures, redo) will be enrolled into the study after a giving informed consent. Selection of patients are directed by randomization. Patient which drop out will be replaced.

Interventions

Cytokine adsorption during CPB

Sponsors

CytoSorbents, Inc
CollaboratorINDUSTRY
Klinikum Nürnberg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
65 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Elective cardiac surgery with CPB * Signed informed consent * CPB time \> 75 min. * Comorbidities: * diabetes mellitus * CHF, NYHA class 1 and 2 * liver dysfunction (1, 2) * kidney dysfunction (1, 2) * hypertension * arteriosclerosis

Exclusion criteria

* Age \< 65 years * Declined informed consent * Planed temperature \< 32 C * Emergency surgery * Preexisting renal replacement therapy * Preexisting kidney transplantation * Administration of immunosuppressants like steroids * AIDS with CD 4 \< 200/ * Participation in other trials

Design outcomes

Primary

MeasureTime frameDescription
Cytokine levels following CPB72 hoursEvaluation of cytokine adsorber effect on cytokine levels intra- and post

Secondary

MeasureTime frameDescription
postoperative renal failure necessitating RRTuntil ICU discharge, expected average 4 daysImpact of intraoperative Cytokine adsorption on postoperative organ function
Level of ferritin72 hoursImpact of intraoperative Cytokine adsorption on iron metabolism
Level of transferrin72 hoursImpact of intraoperative Cytokine adsorption on iron metabolism
Intra- and postoperative catecholamine dosagesuntil ICU discharge, expected average 4 daysImpact of intraoperative Cytokine adsorption on hemodynamic stability
Length of ICU stayuntil discharge from ICU, expected average 4 daysImpact of intraoperative Cytokine adsorption on postoperative patient course
Length of hospital stayup to hospital discharge, expected average 14 daysImpact of intraoperative Cytokine adsorption on postoperative patient course
Level of haptoglobin72 hoursImpact of intraoperative Cytokine adsorption on iron metabolism

Other

MeasureTime frameDescription
Mortality28 daysImpact of intraoperative Cytokine adsorption on postoperative patient course

Countries

Germany

Contacts

Primary ContactGiuseppe Santarpino, MD
giuseppe.santarpino@klinikum-nuernberg.de+4909113985441
Backup ContactTheodor Fischlein, MD
theodor.fischlein@klinikum-nuernberg.de+4909113985441

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026